Media
Explore the media center to get the latest news, insights, and publications showcasing EmitBio’s ongoing journey and industry contributions.
Publications
Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2
Economic and clinical impact of a novel, light based, at-home antiviral treatment on mild-to-moderate COVID-19
A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting
Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue
Visible blue light inactivates SARS-CoV-2 variants and inhibits Delta replication in differentiated human airway epithelia
Presentations
Exploring light as a pan-variant therapeutic for COVID-19; Biosafety Considerations of the Biological Light Unit
A Phase II, Randomized, Sham-Controlled Dose- Finding Study of the RD-X19 Treatment Device in Individuals with Mild-to-Moderate COVID-19
The Impact of Blue-Light Emitting Device on the Loss of Productivity From COVID-19 in North Carolina
News Articles
EmitBio to Present Research on Novel Light-Based Antiviral Therapy at the World Congress on Infectious Diseases (October 23-25, 2023)
COVID-19 treatment at home could come from Durham firm’s blue light tech
Researchers Suggest That Visible Blue Light Is a Safe and Variant-Agnostic Therapy against SARS-CoV-2
Emitbio, BioTech Developing a light Treatment for Corona
Study: EmitBio’s Blue Light Biotech can Eliminate 99.99% of Omicron in Lab Setting
Local Firm to Host Trials for Home COVID Treatment
InnovationRX: The Boomers Are OK; Plus, Covid Mu Variant
This Company Wants To Treat Mild Cases Of Covid With LED Lights
Durham company says its light treatment kills COVID-19 and variants in the throat
Emitbio seeks EUA for light-based COVID-19 treatment to be used at home
NC company develops light-based device to kill COVID-19 in the body; now, they’re seeking emergency authorization
Durham-Based Startup Could Have New COVID-19 Treatment
EmitBio’s technology shows evidence to inactivate multiple coronaviruses
EmitBio Seeks to Provide Light at the End of the COVID-19 Treatment Tunnel
Durham company producing light technology that treats COVID-19
EmitBio Unveils Positive Early Results for Handheld COVID-19 Therapeutic
Press Releases
EmitBio Presenting at the World Congress on Infectious Diseases
Projects Annual Savings of Over $4 Billion
Treatment Effective against Omicron in Vitro
Covering Light to Treat COVID-19 and Other Diseases
Yield 99.99% Reduction of Delta in Human Tissue
Broadly Effective against Coronavirus Variants
Emitbio Reduces Viral Load in Clinical Trial
Emitbio Demonstrates New Treatment Is Effective against Multiple Types of Coronavirus
Emitbio Announces Positive Clinical Results Supporting a Novel Therapeutic for COVID-19
EmitBio Inc. is a life science company developing breakthrough medical devices that change how the world treats respiratory infectious disease.
The EmitBio RD-X19 device is investigational and not currently available for sale